COVID-19 patients (Severe and critical) Early hemoperfusion , Severe and critical COVID-19
Conditions
Interventions
hemoperfusion therapy at least 3 sessions in combination with standard therapy,received standard treatment alone or received less than 3 sessions of hemoperfusion therapy
Experimental Device,No Intervention No treatment
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. COVID-19 patients with age more than 15 year 2. Diagnosed as severe or critical COVID-19 infection 3. Already received favipirair or remdesivir in combination with corticosteroid (more than 6 mg of dexamethasone or equivalent dose) for more than 24-48 hours 4. Hyperinflammatory state including CRP > 75 mg/L , ferritin > 300 ng/ml and serum IL-6 level > 20 pg/ml 5. Hypoxemia with PaO2 / FiO2 < 300 and/or oxygen saturation room air < 92 percent and/or Lung infiltration increasing more than 50 percent within 24-48 hours
Exclusion criteria
Exclusion criteria: 1. Patients in terminal states (estimated no more than 24 hours alive) 2. Pregnancy 3. History of HA-330 catridge or Tocilizumab allergy 4. Recent myocardial infarction within 1 month 5. Persistent shock more than 12 hours 6. Patients who accepted DNR (do not resuscitation)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mortality 28 day 28 day mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| Ventilator day 28 day Ventilator free day | — |
Countries
Thailand
Contacts
Public ContactKarjbundid Surasit
Nakornping hospital
Outcome results
None listed